Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: February 14, 2013
Last updated: January 6, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):